To view presentation slides, please click the individual titles within each session.

Session I: Prevention, Screening, And Genomic Markers
Chair: Alan W. Partin, MD, PhD

Prostate Cancer Screening: What We’ve Learned and Where We Should Go
Gerald L. Andriole, Jr., MD

Early Detection and Family Practice
Matt T. Rosenberg, MD

When to Biopsy: The Role for PSA and Novel Biomarkers
Stacy Loeb, MD

Soy Isoflavones in Prostate Cancer Prevention, Treatment and Survivorship
Omer Kucuk, MD

What Are Currently the Best Decision Markers for Biopsy and Re-Biopsy of the Prostate?
E. David Crawford, MD

Progress in Prostate Cancer Grading
M. Scott Lucia, MD

Targeted Prostate Cancer Screening: Role of Germline Genetic Testing

A. Karim Kader, MD, PhD

Session II: Localized Disease
Chair: James A. Eastham, MD

The Role of Multi-Parametric MRI: Implication and Implementation
Nelson N. Stone, MD

Active Surveillance at Johns Hopkins – Update 2015
Alan W. Partin, MD, PhD

Radical Prostatectomy: Management of Primary From Localized to Oligometastatic Disease
James A. Eastham, MD

Accurate Staging of Prostate Cancer
Phillip J. Koo, MD

Prostate Biopsy and Targeted Therapy
Nelson N. Stone, MD

Strategies of Radiotherapy for Intermediate- to High-risk Prostate Cancer
Daisaku Hirano, MD

Review of Selected Posters

The 4Kscore Test Predicts High Grade Prostate Cancer on Biopsy at PSA Levels < 4ng / mL

Jay R. Newmark, MD

The CCP Score Provides Significant Prognostic Information in Gleason Score ≤ 6 Patients

Michael K. Brawer, MD

Session III: Advanced Disease

Cardiovascular Complications of ADT: Reviewing Preclinical and Clinical Data and Introducing the RADICAL-PC Trial
Jehonathan Pinthus, MD, PhD

Neuroendocrine Prostate Cancer (NEPC): Are We Selecting For It With Our Current Androgen Annihilation?
Jehonathan Pinthus, MD, PhD

Early Chemotherapy for Metastatic Prostate Cancer
Daniel P. Petrylak, MD

Personalized ADT
Thomas E. Keane, MBBCh

Statins, Aspirin, and Metformin (S.A.M.): The Best “Natural” Pills for Patients Concerned About PCa
Mark A. Moyad, MD, MPH

 

Session IV: Advanced And Metastatic Disease
Chair: Neal D. Shore, MD

There Are Newer and More Promising Agents Than Chemotherapy
Neal D. Shore, MD

Current and Future Opportunities Combining Radiation with Immunotherapy
Steven E. Finkelstein, MD

Intermittent Therapy: When To Start, or Restart, and the Role of Imaging
Leonard G. Gomella, MD

Session V: Advanced And Castration-Resistant Disease
Chair: Neal D. Shore, MD

Review of Selected Posters

IMAAGEN Trial Update: Effect of Abiraterone Acetate and Low Dose Prednisone on PSA in Patients With Non-mCRPC

Tracy McGowan, MD

3-Year Follow-up of Chemotherapy Following Radium-223 Dichloride in Castration-Resistant Prostate Cancer Patients with Symptomatic Bone Metastases from ALSYMPCA

Neal D. Shore, MD

Beyond Drugs and Pumps: A New Approach to the Management of Erectile Dysfunction

Kambiz Tajkarimi, MD

Prospective Head to Head Clinical Study of Pharmacokinetic and Pharmacodynamic Properties of Leuprolide Acetate in 2 Formulations: 7.5 Mg Single Depot Subcutaneous Injection vs 7.5 Mg Intramuscular Microsphere Injection.

Neal D. Shore, MD

 

Radiopharmaceuticals: Has There Been Progress?
Neal D. Shore, MD

The Role of the Urologist in the Management of Advanced Prostate Cancer 2016
Raoul S. Concepcion, MD

The Future of Clinical Research in Private Practice: Alive or Dead?
Lawrence I. Karsh, MD